Navigation Links
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Date:3/14/2008

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial of 100 patients that evaluates the safety and efficacy of its lead product, MM-093, in patients suffering from rheumatoid arthritis (RA). MM-093 is a recombinant version of human alpha-fetoprotein (AFP).

The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at 20 centers throughout the United States. The objective of this study is to examine the safety and efficacy of MM-093 in patients with moderate to severe, active RA despite treatment with stable doses of methotrexate. Each patient receives 60mg of MM-093 per week or placebo for 12 weeks and will then be followed for a period of 4 weeks. In addition to evaluating the safety of MM-093, patients will be assessed for changes in the signs and symptoms of their disease using standard clinical outcome measurements for RA, such as ACR20 and DAS28 scores. Patients who complete the study are eligible to participate in an ongoing Open-Label Extension study, which has enrolled over 35 patients to date.

"We are pleased to have completed enrollment and are thankful for the enthusiasm of the investigators who have worked diligently to enroll patients," said Dr. William Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "We believe MM-093 represents a promising and novel approach to the treatment of a broad range of autoimmune diseases. We look forward to completing the study and communicating the results later this year."

In addition to the ongoing studies in RA, MM-093 is currently being tested in a pilot study for patients with certain types of autoimmune uveitis, an inflammatory disorder of the eye.

Merrimack controls a strong intellectual property estate around MM-093 including 15 issued patents and a number of pending applications, both in the U.S. and internationally, which cover composition
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
4. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
11. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Fuisz ( www.fuisz.com ) today announced the issuance ... Stage Door Access to On-Line Vendor Information"). ... patent covers a system that allows a customer or ... product supplier database through the on-line vendor,s system to ...
... help simplify the OR, Ethicon Endo-Surgery, Inc. (EES) today announces ... ever Advanced Energy Generator made to power both ultrasonic and ... use in the operating room. "The operating ... Judith Butt, Theatre Nurse, Prince Charles Hospital, Wales, UK ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces Innovative New Generator to Help Simplify Use of Advanced Energy Technology in the OR 2
(Date:7/12/2014)... July 12, 2014 (HealthDay News) -- Burn injuries increase in ... outdoor grills, say burn experts. Among those most vulnerable to ... the most vulnerable and often get burned by putting their ... Gamelli, director of the burn unit at Loyola University Medical ... "The old adage of ,When you play with fire, ...
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 ... embarrassing, so one of two inventors from Ashland, Va., ... to do this. "This inspired us to conceive of ... prototype of the patent-pending KIDNEY KOVER, which provides an ... bag. It avoids embarrassment, as well as promotes comfort ...
(Date:7/12/2014)... 2014 Wright & Schulte LLC has filed ... Inc., a subsidiary of Johnson & Johnson, on behalf of ... after receiving a metal-on-metal DePuy Pinnacle hip replacement and had ... artificial hip implant. The DePuy hip lawsuit was filed July ... Texas (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip lawsuit ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm who ... (case #59776/2014), announces they have launched a new TV ... popular hair dye, Just For Men, has caused some men ... other areas. In addition to detailing symptoms that are allegedly ... advertisements being run by Wright & Schulte LLC will also ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4
... , SANTA ROSA, Calif., Sept. ... and curvable bone cement delivery needle) and Osseoflex DR (steerable ... CE Mark approval for marketing and clinical use in the ... roughly corresponds to FDA approval in the United States, and ...
... , PEMBROKE, Bermuda, Sept. 21 ... announced today that Linda,McSmith, AVP, Risk Management for Allied World ... Allied World, at the Ohio Association of,Ambulatory Surgery Centers (OAASC) ... September 24-25, 2009. , Ms. McSmith,s ...
... , DEERFIELD, Ill., Sept. 21 ... National Science Teachers Association (NSTA), is pleased to welcome its ... 2009 NSTA New Science Teacher Academy. The national, year-long program ... resources, while providing the support needed to build a strong ...
... LONDON, Sept. 21 Thomson Reuters today launched Thomson Pharma Partnering ... intelligence and sales forecast data to enable quick and credible assessment ... The product will be demonstrated at two upcoming conferences: Pharma Forecasting ... Europe 2009 in Vienna from November 2 to 4. , ...
... The Defense Advanced Research Projects Agency (DARPA), the research arm ... $19.5 million for an effort led by the Duke Institute ... easy-to-use diagnostic device that can reveal who is infected with ... DARPA is interested in such a device because ...
... Building upon four decades of research and ... health information exchange, Regenstrief Institute researchers have developed, ... allow for the bi-directional flow of evidence-based medical ... A demonstration of the pioneering new tools ...
Cached Medicine News:Health News:Osseon Receives CE Mark 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:Thomson Reuters Launches Thomson Pharma Partnering Forecast 2Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Fighting disease outbreaks with 2-way health information exchange 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: